NEW
YORK, Aug. 16, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of ImmunityBio, Inc..
Shareholders who purchased shares of IBRX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/immunitybio-loss-submission-form/?id=43526&from=4
CLASS PERIOD: May 23, 2022
to May 10, 2023
ALLEGATIONS: The complaint alleges that during the class period, Defendants
issued materially false and/or misleading statements and/or failed
to disclose that: (i) ImmunityBio conducted insufficient due
diligence to discover, or else did discover and ignored, Good
Manufacturing Practice ("GMP") deficiencies at its third-party
contract manufacturing organizations ("CMOs") for the antibody
cytokine fusion protein N-803, commercially referred to as
"Anktiva"; (ii) one or more of the Company's third-party CMOs for
Anktiva did in fact suffer from GMP deficiencies; (iii) the
foregoing deficiencies was likely to cause the FDA to reject the
Anktiva Biologics License Application ("BLA") in its present form;
(iv) accordingly, the Company overstated the regulatory approval
prospects for the Anktiva BLA; and (v) as a result, the Company's
public statements were materially false and misleading at all
relevant times.
DEADLINE: August 29, 2023
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/immunitybio-loss-submission-form/?id=43526&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of IBRX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is August 29, 2023. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal
business practices. The Gross Law Firm is committed to ensuring
that companies adhere to responsible business practices and engage
in good corporate citizenship. The firm seeks recovery on behalf of
investors who incurred losses when false and/or misleading
statements or the omission of material information by a company
lead to artificial inflation of the company's stock. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-immunitybio-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-august-29-2023--nasdaq-ibrx-301901660.html
SOURCE The Gross Law Firm